$5.60
0.00 (0%)
Indevus Pharmaceuticals (IDEV.DL)
CAPS Rating:
A biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men's health conditions.

RSS Headlines
Fool UK
Recs
Lots of drugs on the market already that generate substantial revenues, Nebido (blockbuster testosterone drug) approval in reach, Pagoclone and Valstar updates in the near-term are likely.